**Supplementary Table 1.** Characteristics of published studiesreporting clinical outcomes and 15-GEP results

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study**  | **n** | **median follow-up (mths)** | **design** | **overall rate of metastasis** | **univariate hazard ratios** estimated/reported;endpoint HR (95% CI) |
| Onken et al., 2012a | 446 | 17.4 | Prospective | Class 1: 1.1% | reported;MFS 26.4 (8.2-84.6) |
| Class 2: 25.9% |
| Chappell et al., 2012 | 187 | 21.7 | Retrospective | Class 1: 5.1% | estimated;MSS 7.4 (4.0-13.6) |
| Class 2: 34.8% |
| Correa et al., 2014b | 159 | 56.4 | Prospective | Class 1: 4.6% | estimated;MSS 7.4 (4.4-12.2) |
| Class 2: 28.6% |
| Correa et al., 2016 | 299 | 32.2 | Prospective | NR | reported;MSS 7.5 (2.7-20.8) |
| Walter et al., 2016 | 339 | 24.5 | Retrospective | Class 1: 5.8% | reported;MFS 10.3 (4.3-24.8)OS: 8.0 (3.3-19.4) |
| Class 2: 39.6% |
| Demirci et al. 2016 | 293 | 23 | Retrospective | Class 1: 3.6%  | estimated;MFS 9.2 (5.6-15.2) |
| Class 2: 26.5% |
| aOverlap with Walter et al 2016; bOverlap with Correa et al. 2016; CI: confidence interval; MFS: metastasis-free survival; MSS: melanoma-specific survival; NR: not reported; OS: overall survival |